Skip Navigation
Print This Page
Share this page: More

Develop Immunologic Therapies the Block Neurologic Injury

In order to develop novel immunologic therapies that stop injury to the brain and spinal cord, the first step is to define why the immune system goes awry and what happens when the immune system crosses into the central nervous system. These studies need to be translated from the laboratory to animal models of multiple sclerosis (MS) and transverse myelitis (TM).

Definition of immune derangements and neural injury pathways:

The main goal of these studies is to identify immune factors that directly or indirectly mediate neuronal/axonal damage in the CNS, and investigate in vivo (within an animal system) neural consequences of inflammatory and non-inflammatory demyelination.

Identification of the neural consequences of immune effector cells utilizing a human neuronal, neuronal/glial and neuronal/glial/immune cell co-culture system are other important studies towards understand neural injury pathways.

Animal model development:

A first step to confirm if the model of injury created in vitro (outside an animal system) hold true in vivo is to develop an animal model that is similar to the disease that develops in humans. By understanding what the immune derangements and the triggers are, we can further the development of an animal model. Animal models hold great promise in studying new therapies prior to the development of clinical trials.

«« back to Research Overview


Related Links

Attacking Two Brain Disorders on Multiple Fronts
Uncover how Hopkins researchers are finding new treatments and diagnostic tools to treat multiple sclerosis and transverse myelitis.

Looking Forward

Read the latest issue of our newsletter

Looking Forward Fall 2014 cover

Previous Issues

Out-of-State and International Patients - Find Out More


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.